|Bid||0.0000 x 900|
|Ask||0.0000 x 900|
|Day's Range||3.4700 - 3.7400|
|52 Week Range||1.8400 - 8.1600|
|Beta (5Y Monthly)||2.26|
|PE Ratio (TTM)||N/A|
|Earnings Date||Dec 11, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.75|
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), today announced the appointment of Jeffrey Silverman as Vice President of Product Engineering, effective June 14, 2021. Mr. Silverman, an engineering management veteran, brings to OncoSec extensive global industry experience spanning more than 20 years, in the development, manufacturing and scale up of Medical Devices including electroporation and gene delivery equipment for the delivery of DNA drugs in support of cancer an
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that management will present a company overview at the Raymond James Human Health Innovation Conference being held virtually Monday, June 21st – Wednesday, June 23rd, 2021.
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the appointment of Robert M. Schinagl, Ph.D., a biotech industry veteran with over 20 years of experience, as Vice President of Program and Alliance Management, effective May 17, 2021.